Author

X. Agirre

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Research Focus:chromatin & epigenetic regulation· 2 Assay:DNA methylation· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:clustering· 1

Frequent Co-Authors

F. Prosper· 4 shared A. Vilas-Zornoza· 2 shared E. Campo· 2 shared G. Clot· 2 shared J. I. Martin-Subero· 2 shared L. Garate· 2 shared M. Duran-Ferrer· 2 shared M. Kulis· 2 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

F. Prosper

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Cell BiologybioRxivMar 6, 2022

Revealing cell populations catching the early stages of the human embryo development in naive pluripotent stem cells

M. Moya-Jodar, A. Ullate-Agote, P. Barlabe…·X. Aranguren

The paper identifies and characterizes distinct cell populations in naive human induced pluripotent stem cells that resemble early human embryo stages.

DOI 10.1016/j.stemcr.2022.11.015

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivFeb 6, 2020

The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome

M. Duran-Ferrer, G. Clot, F. Nadeu…·J. I. Martin-Subero

This study analyzes DNA methylation in B-cell tumors to show its relation to proliferative history and clinical outcomes, introducing a new mitotic clock for prognosis.

DOI 10.1038/s43018-020-00131-2

humanDNA methylation

𝕏 PostBluesky

Cancer BiologybioRxivSep 12, 2019

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease

A. Garcia-Gomez, T. Li, J. Rodriguez-Ubreva…·E. Ballestar

This study identifies aberrant DNA methylation in mesenchymal stromal cells from myeloma patients and shows that targeting DNMTs and G9a with CM-272 reverses bone loss and reduces tumor burden.

DOI 10.1038/s41467-020-20715-x

humanDNA methylation

𝕏 PostBluesky

Cancer BiologybioRxivAug 20, 2019

Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma

R. Ordonez, M. Kulis, N. Russinol…·J. I. Martin-Subero

The paper identifies aberrant chromatin activation as a common mechanism driving the malignant phenotype in multiple myeloma.

DOI 10.1101/gr.265520.120

humanChIP-seq

𝕏 PostBluesky